U.S. DEGENERATIVE DISC DISEASE TREATMENT MARKET ANALYSIS

U.S. Degenerative Disc Disease Treatment Market, by Treatment (Epidural Steroid Injections, Narcotics (Morphine, Methadone Hydrochloride, Codeine, Hydrocodone, Tramodol, Oxycodone, and Others), Orthobiologics (Includes Biomolecular/Gene Therapy, Cell-based Therapy, and Tissue-engineered Products) Phase I, Phase II, and Phase III), by Disease Indication (Early Stage, Mid Stage, and Late Stage), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Aug 2021
Code : CMI4590
Pages :179
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Potential side effects of drugs used in the treatment of degenerative disc disease
High cost of surgery

U.S. Degenerative Disc Disease Treatment Market: Restraint

The major factors that may hinder growth of the U.S. degenerative disc disease treatment market include potential side effects of drugs used in the treatment of degenerative disc disease and high cost of surgery. For instance, according to the article published in the Spine Health in 2015, the cervical artificial disc replacement surgery cost around US$ 35,000 in the U.S. Moreover, according to the New Choice Health, Inc., a medical adviser company, the average cost of disc replacement surgery procedures ranges from US$ 16,700 – US$ 45, 800 in the U.S.

Increasing cause of lower back pain & neck pain in adults and increasing geriatric population is expected to drive the market growth during the forecast period.